Revenue Update on Catalent Inc(NYSE:CTLT)

Catalent Inc(NYSE:CTLT) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-hours on Aug 29, 2016. Company reported revenue of $532.20M. Analysts estimated a revenue of $502.25M. Earnings per share were $0.52. Analysts had estimated an EPS of $0.53.

In a different note, On Jun 21, 2016, Wells Fargo said it Upgrades its rating on Catalent Inc. The shares have been rated ‘Outperform’ by the firm. On Jun 20, 2016, Bank of America said it Upgrades its rating on Catalent Inc. The shares have been rated ‘Buy’ by the firm.

Catalent Inc (CTLT) remained unchanged at the close of Thursday session. Even as the volume increased to 7,11,891 ,the shares failed to make any impression and ended at 0 points or 0.00% at $25.23. The trading session commenced at $25.15 and the stock hit a high of $25.62 and touched $24.9 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $32.24 and the 52-week low is $18.92. The company has a market cap of $3,147 M and has approximately 12,47,44,437 outstanding shares.

Several Insider Transactions has been reported to the SEC. On Jun 1, 2016, Matthew M Walsh (officer ) sold 21,197 shares at $28.85 per share price.Also, On Aug 19, 2015, John R Chiminski (director officer ) sold 38,505 shares at $33.87 per share price.On Apr 3, 2015, Scott Houlton (officer ) sold 16,253 shares at $30.61 per share price, according to the Form-4 filing with the securities and exchange commission.

Catalent Inc. is a provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. The Company’s segments include Oral Technologies Medication Delivery Solutions and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies including formulation development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle. The Medication Delivery Solutions segment provides formulation development and manufacturing services for delivery of drugs and biologics administered through injection inhalation and ophthalmic routes using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing packaging storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Catalent Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Catalent Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.